Qu, W., Gao, J., Zhang, B., Yang, M., Wang, Y., Liu, Y., Guo, Y., Guo, S., Huang, J.

Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial

30 de October de 2025 by Qu, W., Gao, J., Zhang, B., Yang, M., Wang, Y., Liu, Y., Guo, Y., Guo, S., Huang, J.

Background
Cadonilimab, a bispecific antibody simultaneously targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4, may further boost antitumor activity compared with PD-1 or programmed cell death ligand 1 (PD-L1) inhibitors. H…